Utrogestan

Description

For oral administration:
– threatening abortion or prevention of habitual abortion due to progesterone deficiency;
– infertility due to luteal insufficiency;
– premenstrual syndrome;
– violations of the menstrual cycle due to violations of ovulation or anovulation;
– fibrocystic mastopathy;
– period of menopausal transition;
– menopausal (replacement) hormone therapy (MHT) in peri- and postmenopause (in combination with estrogen-containing drugs).
For intravaginal use:

– MHT in case of progesterone deficiency with non-functioning (absent) ovaries (egg donation);
– prevention (prevention) of preterm birth in women at risk (with shortening of the cervix and / or the presence of anamnestic data of preterm birth and / or premature rupture of the membranes);
– support of the luteal phase during preparation for in vitro fertilization;
– support of the luteal phase in a spontaneous or induced menstrual cycle;
premature menopause;
– MHT (in combination with estrogen-containing drugs);
– infertility due to luteal insufficiency;
– threatening abortion or prevention of habitual abortion due to lack of progesterone.

Active ingredient: Progesterone

Prescription medicine.